sertindole (Serdolect)

01/01/2000 - "Sertindole is effective against positive and negative symptoms of schizophrenia within the dose range 12-24 mg daily, with an optimal starting dose of 16 mg daily. "
01/01/2004 - "In pivotal clinical trials, sertindole has demonstrated significantly greater efficacy than placebo against both the positive and negative symptoms of schizophrenia. "
01/01/1998 - "Sertindole appears to be an effective long-term treatment for schizophrenia."
03/01/2012 - "The efficacy of sertindole in the treatment of positive and negative schizophrenia symptoms has been shown in various studies. "
01/01/2010 - "The sertindole-induced improvement in cognitive function in this animal model suggests relevance for the management of cognitive deficit symptoms in schizophrenia."

11/01/1997 - "Sertindole should prove to be a very useful addition to the therapeutic options available for the treatment of psychotic disorders."
04/01/2012 - "Four patients randomized to sertindole experienced a significant worsening of psychosis, and 2 of them required psychiatric admission. "
01/01/2005 - "Clinical observations of sertindole in 53 hospitalised patients with psychotic disorders."
07/01/2000 - "We report drug surveillance data in 34 comorbid and comedicated sertindole treated patients suffering from different psychotic disorders. "
11/01/1998 - "[Management of schizophrenic psychoses: a one-year experience with Serdolect]."

11/01/2005 - "However, the beneficial effect of sertindole on severe, late-occurring movement disorders, as observed in four difficult-to-treat patients, appears to be promising."
11/01/2005 - "Three of the four patients apparently recovered from the movement disorders after switching to sertindole. "
04/15/2009 - "Sertindole may induce fewer movement disorders, but more cardiac effects, weight change and male sexual dysfunction than risperidone. "
10/01/2009 - "Sertindole, a 2nd generation antipsychotic with low movement disorder side effects, was compared with haloperidol in a 6-week crossover study. "
01/01/2000 - "Sertindole was associated with fewer movement disorders than haloperidol but was shown to cause more weight gain (NNH=9 RR 6.33, CI 1.92 to 20.92), rhinitis (NNH=8, RR 1.74, CI 1,28 to 2.36) and possibly male sexual dysfunction. "

09/07/2010 - "Although previous data suggested that sertindole was well tolerated and had good efficacy against both positive and negative symptom clusters, reports of QT prolongation with sertindole prompted its voluntary removal from the market in 1998. "

11/01/2010 - "We report the case of a 46-year-old patient with schizophrenia who developed a rebound insomnia confirmed by polysomnography after discontinuation of long-term treatment with clozapine and changing to sertindole therapy. "
11/01/2010 - "Combined treatment with quetiapine and sertindole in therapy refractory insomnia after clozapine discontinuation."
11/01/2010 - "In conclusion, the combination of sertindole and quetiapine might be a safe and effective combination in therapy-refractory insomnia after clozapine discontinuation in schizophrenia."